← All trials
NCT02965456
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 30, 2015
- Primary completion
- Feb 23, 2017
- Completion date
- Apr 12, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 820
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Bausch Health CompaniesLead sponsor
- TKL ResearchStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.